Skip to main content
. Author manuscript; available in PMC: 2014 Apr 30.
Published in final edited form as: Int J Hematol. 2013 Sep;98(3):275–292. doi: 10.1007/s12185-013-1406-9

Figure 4. Proposed clinical study for newly diagnosed GVHD.

Figure 4

Biomarker cutpoints will determine if a patient is at high or low risk of treatment unresponsiveness at the diagnosis of GVHD. Low risk patients will receive the standard GVHD treatment; high risk patients will be randomized to receive either the standard GVHD treatment or an intensified GVHD treatment. Comparison of outcomes from the randomized high risk groups will show if intensified treatment at onset of GVHD improves responses rates and lowers mortality in high risk patients identified by biomarkers.